Oral PCSK9 Inhibitors: Will They Work?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Drug Development

Background:

• Lowering low-density lipoprotein cholesterol (LDL-C) is essential for preventing atherosclerotic cardiovascular disease.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a modern therapeutic class for managing hypercholesterolemia.
• Current approved PCSK9 inhibitors are administered via injection.

Purpose of the Study:

• To review the current research landscape of orally administered PCSK9 inhibitors.
• To highlight the development and early findings of novel small molecule PCSK9 inhibitors.

Main Methods:

• Review of recent scientific literature and clinical trial data on oral PCSK9 inhibitors.
• Analysis of efficacy, safety, and tolerability data from early-stage studies.

Main Results:

• Several oral small molecule PCSK9 inhibitors have been developed, including enlicitide decanoate and AZD0780.
• Enlicitide decanoate demonstrated up to 66% LDL-C reduction with good safety.
• AZD0780 showed 52% LDL-C reduction and can be used with statins.

Conclusions:

• Oral PCSK9 inhibitors are demonstrating promising results in early clinical studies.
• Successful outcome trials could lead to a safe, effective, and convenient oral therapy for hypercholesterolemia.
• These agents may offer a valuable alternative to injectable therapies, increasing patient access to effective LDL-C lowering.